The Outcome of


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 24 11 2019
revised: 15 03 2020
accepted: 14 04 2020
pubmed: 19 4 2020
medline: 13 3 2021
entrez: 19 4 2020
Statut: ppublish

Résumé

During our efforts to develop tumor-infiltrating lymphocyte (TIL) therapy to counter the devastating recurrence rate in patients with primary resectable pancreatic ductal adenocarcinoma (PDA), we found that PDA TILs can readily be expanded We compared the clonal composition of TIL preparations before and after We found that the TIL TCR repertoire changes dramatically during Culture-induced changes in clonal composition are likely to affect tumor reactivity of TIL preparations. TCR deep sequencing provides important insights into the factors that govern the outcome of

Identifiants

pubmed: 32303540
pii: 1078-0432.CCR-19-3845
doi: 10.1158/1078-0432.CCR-19-3845
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

4289-4301

Commentaires et corrections

Type : CommentIn
Type : CommentOn

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Isabel C Poschke (IC)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany. i.poschke@dkfz.de.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Jessica C Hassel (JC)

Department of Dermatology and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.

Aaron Rodriguez-Ehrenfried (A)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Katharina A M Lindner (KAM)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Ignacio Heras-Murillo (I)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Lena M Appel (LM)

Division of Theoretical Systems Biology, German Cancer Research Center and BioQuant Center, University of Heidelberg, Heidelberg, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich (TUM), Munich, Germany.

Johanna Lehmann (J)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Tanja Lövgren (T)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Stina L Wickström (SL)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Claudia Lauenstein (C)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Jasmin Roth (J)

Department of Dermatology and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.

Anna-Katharina König (AK)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.

John B A G Haanen (JBAG)

Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Joost van den Berg (J)

Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Rolf Kiessling (R)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Frank Bergmann (F)

Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Michael Flossdorf (M)

Division of Theoretical Systems Biology, German Cancer Research Center and BioQuant Center, University of Heidelberg, Heidelberg, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich (TUM), Munich, Germany.

Oliver Strobel (O)

Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Rienk Offringa (R)

Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH